Erasca, Inc. Operating Expenses
Erasca, Inc. (ERAS) reported Operating Expenses of $47.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Erasca, Inc. operating expenses for the quarter ending 2026-06-30 was $47.62M, a 24.90% increase year-over-year.
- Erasca, Inc. operating expenses for the quarter ending 2026-03-31 was $187.91M, a 427.40% increase year-over-year.
- Erasca, Inc. operating expenses for the quarter ending 2025-12-31 was $32.60M, a 8.70% decline year-over-year.
- Erasca, Inc. operating expenses for the quarter ending 2025-09-30 was $34.55M, a 7.24% decline year-over-year.
- Erasca, Inc. operating expenses for fiscal 2025 was $140.91M, a 21.54% decline from fiscal 2024.
- Erasca, Inc. operating expenses for fiscal 2024 was $179.59M, a 26.89% increase from fiscal 2023.
- Erasca, Inc. operating expenses for fiscal 2023 was $141.53M, a 42.81% decline from fiscal 2022.
- Erasca, Inc. operating expenses for fiscal 2022 was $247.45M, a 98.15% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.62M 10-Q · filed 2026-08-11 | $235.53M 10-Q · filed 2026-08-11 | $268.13M derived: sum of 3 quarters · filed 2026-08-11 | $302.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $187.91M 10-Q · filed 2026-05-11 | $220.51M derived: sum of 2 quarters · filed 2026-05-11 | $255.06M derived: sum of 3 quarters · filed 2026-05-11 | $293.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $32.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $67.15M derived: sum of 2 quarters · filed 2026-03-12 | $105.28M derived: sum of 3 quarters · filed 2026-08-11 | $140.91M 10-K · filed 2026-03-12 |
| 2025-09-30 | $34.55M 10-Q · filed 2025-11-12 | $72.67M derived: sum of 2 quarters · filed 2026-08-11 | $108.30M 10-Q · filed 2025-11-12 | $144.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $38.13M 10-Q · filed 2026-08-11 | $73.75M 10-Q · filed 2026-08-11 | $109.47M derived: sum of 3 quarters · filed 2026-08-11 | $146.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $35.63M 10-Q · filed 2026-05-11 | $71.34M derived: sum of 2 quarters · filed 2026-05-11 | $108.58M derived: sum of 3 quarters · filed 2026-05-11 | $176.37M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $35.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $72.95M derived: sum of 2 quarters · filed 2026-03-12 | $140.74M derived: sum of 3 quarters · filed 2026-03-12 | $179.59M 10-K · filed 2026-03-12 |
| 2024-09-30 | $37.24M 10-Q · filed 2025-11-12 | $105.02M derived: sum of 2 quarters · filed 2025-11-12 | $143.88M 10-Q · filed 2025-11-12 | $177.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $67.78M 10-Q · filed 2025-08-12 | $106.63M 10-Q · filed 2025-08-12 | $140.50M derived: sum of 3 quarters · filed 2025-08-12 | $175.16M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $38.85M 10-Q · filed 2025-05-13 | $72.72M derived: sum of 2 quarters · filed 2025-05-13 | $107.38M derived: sum of 3 quarters · filed 2025-05-13 | $143.35M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $33.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $68.53M derived: sum of 2 quarters · filed 2025-03-20 | $104.50M derived: sum of 3 quarters · filed 2025-03-20 | $141.53M 10-K · filed 2025-03-20 |
| 2023-09-30 | $34.66M 10-Q · filed 2024-11-12 | $70.63M derived: sum of 2 quarters · filed 2024-11-12 | $107.65M 10-Q · filed 2024-11-12 | $245.73M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $35.97M 10-Q · filed 2024-08-12 | $73.00M 10-Q · filed 2024-08-12 | $211.07M derived: sum of 3 quarters · filed 2024-08-12 | $248.03M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $37.02M 10-Q · filed 2024-05-08 | $175.10M derived: sum of 2 quarters · filed 2024-05-08 | $212.06M derived: sum of 3 quarters · filed 2024-05-08 | $247.97M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $138.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $175.04M derived: sum of 2 quarters · filed 2024-03-27 | $210.94M derived: sum of 3 quarters · filed 2024-03-27 | $247.45M 10-K · filed 2024-03-27 |
| 2022-09-30 | $36.96M 10-Q · filed 2023-11-09 | $72.87M derived: sum of 2 quarters · filed 2023-11-09 | $109.37M 10-Q · filed 2023-11-09 | $140.42M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $35.91M 10-Q · filed 2023-08-10 | $72.41M 10-Q · filed 2023-08-10 | $103.46M derived: sum of 3 quarters · filed 2023-08-10 | $149.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $36.51M 10-Q · filed 2023-05-15 | $67.55M derived: sum of 2 quarters · filed 2023-05-15 | $113.60M derived: sum of 3 quarters · filed 2023-05-15 | $141.78M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $31.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $77.09M derived: sum of 2 quarters · filed 2023-03-23 | $105.28M derived: sum of 3 quarters · filed 2023-03-23 | $124.88M 10-K · filed 2023-03-23 |
| 2021-09-30 | $46.04M 10-Q · filed 2022-11-09 | $74.23M derived: sum of 2 quarters · filed 2022-11-09 | $93.83M 10-Q · filed 2022-11-09 | $160.81M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $28.18M 10-Q · filed 2022-08-11 | $47.79M 10-Q · filed 2022-08-11 | $114.76M derived: sum of 3 quarters · filed 2022-08-11 | $125.92M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $19.61M 10-Q · filed 2022-05-12 | $86.58M derived: sum of 2 quarters · filed 2022-05-12 | $97.74M derived: sum of 3 quarters · filed 2022-05-12 | $105.02M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $66.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $78.13M derived: sum of 2 quarters · filed 2022-03-24 | $85.42M derived: sum of 3 quarters · filed 2022-03-24 | $109.25M 10-K · filed 2022-03-24 |
| 2020-09-30 | $11.16M 10-Q · filed 2021-11-10 | $18.45M derived: sum of 2 quarters · filed 2021-11-10 | $42.28M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $7.28M 10-Q · filed 2021-08-26 | $31.12M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |